CN101316859A - 用于治疗和预防病毒感染的环孢菌素a的芳基烷基和杂芳基烷基衍生物 - Google Patents

用于治疗和预防病毒感染的环孢菌素a的芳基烷基和杂芳基烷基衍生物 Download PDF

Info

Publication number
CN101316859A
CN101316859A CNA200680044682XA CN200680044682A CN101316859A CN 101316859 A CN101316859 A CN 101316859A CN A200680044682X A CNA200680044682X A CN A200680044682XA CN 200680044682 A CN200680044682 A CN 200680044682A CN 101316859 A CN101316859 A CN 101316859A
Authority
CN
China
Prior art keywords
compound
acid
hcv
present
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200680044682XA
Other languages
English (en)
Chinese (zh)
Inventor
大卫·兰威克·霍克
李科强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scynexis Inc
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of CN101316859A publication Critical patent/CN101316859A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA200680044682XA 2005-09-30 2006-10-02 用于治疗和预防病毒感染的环孢菌素a的芳基烷基和杂芳基烷基衍生物 Pending CN101316859A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72267805P 2005-09-30 2005-09-30
US60/722,678 2005-09-30

Publications (1)

Publication Number Publication Date
CN101316859A true CN101316859A (zh) 2008-12-03

Family

ID=37561742

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200680044682XA Pending CN101316859A (zh) 2005-09-30 2006-10-02 用于治疗和预防病毒感染的环孢菌素a的芳基烷基和杂芳基烷基衍生物

Country Status (8)

Country Link
US (1) US8329658B2 (https=)
EP (1) EP1931696B1 (https=)
JP (1) JP5322647B2 (https=)
CN (1) CN101316859A (https=)
AT (1) ATE498630T1 (https=)
CA (1) CA2623864C (https=)
DE (1) DE602006020152D1 (https=)
WO (1) WO2007041631A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869367A (zh) * 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽
CN104870007A (zh) * 2012-10-19 2015-08-26 西尼克斯公司 新的抗病毒大环化合物
CN108025039A (zh) * 2015-06-30 2018-05-11 西普拉里斯有限公司 新颖的大环化合物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
SI1802650T1 (sl) * 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
EP1931696B1 (en) 2005-09-30 2011-02-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
JP5517454B2 (ja) 2005-09-30 2014-06-11 スシネキス インク C型肝炎感染の治療及び予防のための方法及び医薬組成物
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
CN101502196A (zh) * 2006-06-02 2009-08-05 克洛德·安妮·佩里西恩 激活电子的管理
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
CN102083852A (zh) * 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
KR20110111321A (ko) 2009-01-30 2011-10-10 이난타 파마슈티칼스, 인코포레이티드 C형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
WO2011082289A1 (en) 2009-12-30 2011-07-07 Scynexis Inc. Cyclosporine analogues
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
BR112013014890B1 (pt) 2010-12-15 2023-10-24 Contravir Pharmaceuticals, Inc Composto análogo de moléculas pertencentes à família ciclosporina, composição farmacêutica compreendendo o mesmo, uso terapêutico ou profilático do referido composto e processos para a preparação dos mesmos
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
JP2016538317A (ja) 2013-08-26 2016-12-08 エナンタ ファーマシューティカルズ インコーポレイテッド C型肝炎を防止または治療するための新規シクロスポリン類似体
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
KR20260018851A (ko) * 2023-06-02 2026-02-09 파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드 사이클로필린 저해제 및 그 용도

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4814323A (en) 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5294604A (en) 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
EP0672127B1 (en) * 1991-10-12 1999-01-07 The Regents Of The University Of California Use of thiol redox proteins for reducing disulfide bonds
PL324531A1 (en) 1995-07-17 1998-06-08 Chem Ag C Derivatives of cyclosporin effective against hiv virus
JP3089350B2 (ja) 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2772768B1 (fr) 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
CN1205220C (zh) 1998-06-12 2005-06-08 斯-凯穆公司 新颖的环孢菌素
FR2780061B1 (fr) 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
AU759480B2 (en) 1998-07-01 2003-04-17 Debiopharm S.A. Novel cyclosporin with improved activity profile
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6521595B1 (en) 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
DK1385870T3 (da) 2000-07-21 2010-07-05 Schering Corp Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
AP2004003069A0 (en) 2001-11-27 2004-06-30 Anadys Pharmaceuticals Inc 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
US6987090B2 (en) 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR20040039622A (ko) 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'-c-甲基-3'-o-l-缬氨酸酯核糖呋喃基胞苷
WO2005000308A2 (en) 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
AU2005261838A1 (en) 2004-07-13 2006-01-19 Novartis Ag Cyclosporins to treat Alzheimer's disease
US7671017B2 (en) 2004-07-14 2010-03-02 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)
US20060025267A1 (en) 2004-07-29 2006-02-02 Mircea Gradu Differential with torque vectoring capabilities
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
DK1793844T3 (da) 2004-10-01 2011-03-21 Debiopharm Sa Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion
SI1802650T1 (sl) 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
AU2005322241B2 (en) 2004-12-23 2010-02-18 Novartis Ag Compounds for flaviviridae treatment
WO2006071619A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
JP5517454B2 (ja) 2005-09-30 2014-06-11 スシネキス インク C型肝炎感染の治療及び予防のための方法及び医薬組成物
EP1931696B1 (en) 2005-09-30 2011-02-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
WO2008143996A1 (en) 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
CN102083852A (zh) 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
US20090306033A1 (en) 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
MX2011007194A (es) 2009-01-07 2013-07-12 Scynexis Inc Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc).
JP2012514605A (ja) 2009-01-07 2012-06-28 サイネクシス,インコーポレーテッド Hcvおよびhiv感染の治療への使用におけるシクロスポリン誘導体
US20110144005A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869367A (zh) * 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽
CN104870007A (zh) * 2012-10-19 2015-08-26 西尼克斯公司 新的抗病毒大环化合物
CN108025039A (zh) * 2015-06-30 2018-05-11 西普拉里斯有限公司 新颖的大环化合物
CN108025039B (zh) * 2015-06-30 2022-07-29 西普拉里斯有限公司 新颖的大环化合物

Also Published As

Publication number Publication date
EP1931696A1 (en) 2008-06-18
DE602006020152D1 (de) 2011-03-31
JP2009510128A (ja) 2009-03-12
US8329658B2 (en) 2012-12-11
US20090298751A1 (en) 2009-12-03
CA2623864C (en) 2014-12-16
EP1931696B1 (en) 2011-02-16
CA2623864A1 (en) 2007-04-12
JP5322647B2 (ja) 2013-10-23
WO2007041631A1 (en) 2007-04-12
ATE498630T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
CN101316859A (zh) 用于治疗和预防病毒感染的环孢菌素a的芳基烷基和杂芳基烷基衍生物
JP4060801B2 (ja) Ns3(c型肝炎)の抑制のための置換キノリンのヒドロキシプロリンエーテルを有するトリペプチド
RU2399628C2 (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
RU2440822C2 (ru) Способы и фармацевтические композиции для лечения и профилактики инфекции гепатита с
JP5820722B2 (ja) シクロスポリン類似体及びhcv感染の治療におけるその使用
CN103153330A (zh) 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用
CN102307892A (zh) 环孢菌素a的衍生物
US20110144005A1 (en) Novel cyclic peptides
CN106883279B (zh) 一种前药、其制备方法、药物组合物及其用途
US20090306033A1 (en) Novel cyclic peptides
KR20120125610A (ko) 시클로스포린 유사체
CN104870007A (zh) 新的抗病毒大环化合物
CN101316606B (zh) 治疗和预防丙型肝炎感染的方法和药物组合物
CN105777829B (zh) 一种含有类核苷结构的前药、其制备方法、药物组合物及其用途
HK1125953A (en) Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1125953

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20081203

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1125953

Country of ref document: HK